Boston Scientific Launches Emerge™ PTCA Balloon Dilatation Catheter in the U.S.

NATICK, Mass., Sept. 27, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge™ Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter and has begun  marketing the device in the United States.  The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in coronary arteries.  Both the Monorail^® and Over-The-Wire (OTW) options are available.  The Emerge Catheter has been commercially available in CE Mark countries since earlier this year.

"The Emerge Balloon Catheter combines Boston Scientific's innovative balloon technologies into a single platform," said J. Tift Mann, III, M.D., at Wake Heart & Vascular, Raleigh, North Carolina.  "The result is exceptional deliverability and reliable performance in a wide range of anatomy and lesion types."

The Emerge Balloon Catheter is available in a wide array of balloon diameters from 1.5 mm up to 4.0 mm, with balloon lengths ranging from 8 mm up to 30 mm.  Both the Monorail and OTW catheters are available with two distinct shaft technologies designed to provide versatility in addressing different clinical situations.  The "Push Technology" (1.5 mm) offers a single-segment inner shaft for enhanced pushability.  The "Workhorse Technology" (1.5 mm to 4.0 mm) features a bi-segment inner shaft designed for excellent deliverability without sacrificing push.  

"Boston Scientific is committed to delivering innovative technology that enables physicians to improve outcomes for patients undergoing coronary interventions," said Kevin Ballinger, president of the Interventional Cardiology Division at Boston Scientific.  "The Emerge Balloon Catheter further enhances the Boston Scientific portfolio by offering a versatile platform with a range of options and features that allow physicians to select the appropriate balloon based on clinical need."

Coronary artery disease represents the leading cause of death in the United States, accounting for more than 870,000 deaths each year[1].

PTCA balloon dilatation catheters are used in coronary angioplasty and stenting procedures to open arteries blocked by atherosclerosis, which if left untreated can cause angina and heart attack.

[1] Source: http://www.americanheart.org/downloadable/heart/1166712318459HS_StatsInsideText.pdf

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our business plans, markets for our products, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

SOURCE Boston Scientific Corporation